What have people felt on Tirzepatide, and which risks need care?
Which Tirzepatide effects does this page explain?
Given each week as a shot, tirzepatide treats type 2 diabetes and obesity, and this page reports what people felt and what trials measured about weight and blood sugar. Outside trials, people have described less hunger, more energy, and better sleep. Some felt sick to their stomach.
Those accounts and trial results aren't the same kind of proof. Personal reports tell you what someone noticed. The FDA label and trials tell you which changes were checked in set groups. Both can help you form questions for your doctor. This isn't medical advice.
What changes have Tirzepatide users talked about?
People using tirzepatide for care or research have said these things happened. The accounts aren't results from a controlled study, and no trial has tested them together. No doses are given here.
Less hunger and fewer thoughts about food — often reported People say the pull toward meals and snacks can grow quiet. Some even forget a meal because they don't feel the urge. After several trials ended, researchers asked people what had helped most. Across the trial groups, 79–91% named less hunger.
More energy and less tiredness — often reported Across several sets of talks, 62–79% said they felt more awake as weight fell. Some felt tired from week two through week four while eating less. Most later said their energy rose.
Better mood and more trust in themselves — often reported When trials ended, 47–55% said they felt more hopeful and sure of themselves. A few single-person reports also noted less low mood as weight fell. Some people felt no mood change.
Better sleep and less sleep apnea trouble — reported at times People spoke of falling asleep faster and waking more rested. Some snored less. Some with sleep apnea needed less help from a CPAP machine, which pushes air through a mask while they sleep.
Better blood sugar and blood fats — reported at times People reported lower sugar readings. Some also had lower triglycerides, a type of fat measured in blood, and better cholesterol results. A few needed less insulin. In one trial, 96% named better blood sugar as a main gain.
Less joint pain and easier movement — reported at times After a large weight loss, some people felt less pain in their knees, hips, and back. Walking felt easier too. Some said they used fewer pain pills.
Nausea after a dose goes up — often reported About 25–50% of users in these reports named nausea. It was often worst in the week or two after a dose rose. The nausea often faded from week two through week four. Most called it bearable.
Constipation, loose stools, or both — often reported Some people were constipated for a few days, then had loose stools. Food leaves the stomach more slowly with tirzepatide. Bowel trouble often eased as their bodies adjusted.
Redness or soreness where the shot went in — often reported Safety reports listed more than 19,000 cases from 2022 through early 2025. The reports named red skin, itching, soreness, bruises, or small lumps. Most cleared in two to five days. This count doesn't show how often the problem happened because no total number of users came with it.
Egg-smelling burps — reported at times About 3–5% of later safety reports named foul burps. Slower stomach movement or changes in gut germs may play a part. The reports can't prove the cause.
Food tastes odd or seems less tempting — reported at times Some people noticed a metal taste. Foods they once liked seemed too sweet, rich, or hard to face. This often eased after the first weeks or once the dose stayed the same.
Worry about lost muscle — reported at times Some people who lift weights said their strength fell. Trial scans suggest about 25% of lost weight was muscle and other tissue that wasn't fat.
Weeks when weight stops falling — often reported People and doctors often talk about a few weeks with no scale change. This happened most from month three through month six.
Hair thinning or shedding — reported at times Some people shed more hair after starting, often from month three through month six. Fast weight loss may bring this on. Direct harm from the drug may not. Doctors call this short-term shedding after strain on the body. Trials found hair loss in about 4–5% of people, compared with 1% given placebo, a shot with no tirzepatide. Your own mix may differ. These reports can give you words for a doctor visit, but they can't prove what caused a change at home.
Which Tirzepatide risks need a closer look?
The FDA label and reviews give the warnings below. Each number comes from the named study. Your doctor can weigh these risks against your health.
Stomach and bowel trouble as doses rise Across 13 trials, the main harms were nausea, vomiting, loose stools, constipation, and low hunger. They happened more often than with placebo, a shot with no tirzepatide [17][18][19][20]. One safety review found that trouble began after about 16 days. Most cases began before the third month ended. Most were mild or moderate, but these problems caused the most people to stop.
Thyroid tumors found in rats and mice The FDA's strongest warning comes from rats and mice, in which drugs from this group caused more tumors in hormone-making thyroid cells as doses and time on the drug rose [21]. No one knows whether the same harm occurs in people. The label bars use if you or someone in your family has had medullary thyroid cancer, the kind that starts in those hormone-making cells. Ask your doctor which relatives count as family history. The label also bars use with type 2 multiple endocrine neoplasia, an inherited illness that can cause tumors in several glands [21][22]. Human trials haven't proved this animal risk.
Pancreatitis Pancreatitis is a swollen, painful pancreas, and although a review of nine trials didn't find a clear rise against other care, the authors couldn't be 95% sure that risk rose [15]. Another study compared similar people who had pancreatitis before. Within five years, it returned in 6.2% of tirzepatide users. That was lower than among people who didn't use tirzepatide [16]. The label still warns about the risk. Severe belly pain that won't stop needs prompt care.
Gallstones and gallbladder trouble One review combined nine trials with 9,871 people and found gallbladder or bile-duct trouble about 1.97 times as likely as with other care, with the authors 95% sure chance didn't explain the rise [15]. A second review combined 12 trials. It found 1.52 times the rate for that group of problems and 1.67 times the rate for gallstones [24]. Fast weight loss can also cause gallstones. Seeing the link more than once gives doctors reason for care.
Low blood sugar with some diabetes drugs Tirzepatide makes the pancreas release insulin mainly while your blood holds plenty of sugar. Very low blood sugar isn't common with tirzepatide alone. Risk rises with insulin or a sulfonylurea, a diabetes pill that can release insulin when sugar is low. The FDA label says a doctor may lower one of those drugs [21]. Among older adults with type 2 diabetes in the SURPASS trials, rates stayed much the same with or without them [26].
Food left in the stomach before a procedure Tirzepatide slows the stomach for a time. Food may remain before a scope test, deep sleep medicine, or an operation. That food could enter the lungs [27][28]. Tirzepatide remains in your blood for about five days. Reviewers discuss longer fasting, a stomach ultrasound, or medicine that moves food along. Your care team decides what fits you.
Loss of muscle and other tissue In a SURMOUNT-1 scan study, about 25% of lost weight came from muscle and other tissue that wasn't fat. About 75% came from fat [23]. A wider review found 28% as the middle result: half of its findings were lower, and half were higher. Another review likened fast muscle loss to a decade or more of aging [25]. Doctors don't yet know how much that changes strength or health.
Too little fluid and sudden kidney trouble Long spells of vomiting or loose stools can dry you out. Drinking much less adds to the risk. Kidney strain may be worse for someone already short of fluid or taking water pills or some blood-pressure pills [20][17]. Large trials and patient reviews haven't found a clear rise in sudden kidney injury across all users. Some results hint that kidney health may worsen more slowly in people at high risk, but that hasn't been proved.
Birth-control pills may work less well as doses rise Because tirzepatide slows the stomach, the body may take in pills less well. The FDA label says birth-control pills may work less well at the start and after each dose rise [21][28]. During that time, the label suggests a method that isn't swallowed or a barrier method.
Weight often returns after the drug stops Weight loss tends to last only while care continues. Combined follow-up results found about 9.7 kg regained after people stopped semaglutide or tirzepatide [29]. In SURMOUNT-4, people moved to placebo regained weight. People who stayed on tirzepatide lost more. Greater regain came with worse heart and blood-sugar risk signs [30][31]. These results point toward long-term care instead of brief use.
More people stopped because of side effects A review of three trials found that 32% more people stopped tirzepatide than dulaglutide, another diabetes shot. Stomach and bowel trouble caused most of those stops [32]. A later safety review found that mistakes while giving a dose were the most common kind of report [33]. Clear help with the shot matters.
Hair loss Some people had short-term shedding after fast weight loss. The strain of losing weight may cause the shedding, rather than direct harm from the drug. Hair often grows back when weight stays steady [34]. Your prescriber can explain which warnings fit you. Call your care team when vomiting or loose stools are strong, lasting, worrying, or hard to manage.
How did Tirzepatide move from animal tests to people?
In 2018, researchers first reported that tirzepatide, a 39-amino-acid peptide or short protein chain, acted in cells like GIP and GLP-1, two gut hormones that help after food. In mice, tirzepatide lowered blood sugar and weight more than a drug that copied GLP-1 alone. Mice can't predict your result. A Phase 1 study, an early test in 142 people, found that a weekly shot could work. One paper covered both the lab and human work [1]. Later cell tests found that the GIP and GLP-1 actions weren't equal [2].
Next, SURPASS trials included adults with type 2 diabetes. SURMOUNT trials included adults with obesity. Trials against semaglutide, another weekly shot, found larger blood sugar and weight drops with tirzepatide [3][5][6]. The FDA cleared tirzepatide for type 2 diabetes in May 2022 and long-term weight care in November 2023. Clearance for serious sleep apnea in adults with obesity came later [11][12].
Later trials asked about sleep apnea, heart failure, and severe fatty liver disease [14][13][35]. Those human trials add facts about benefits and harms. They don't make a mouse result true for every person. Your doctor can tell you which trial is closest to your health.